HK Stock MarketDetailed Quotes

HENGRUI PHARMA (01276)

Watchlist
  • 73.000
  • +1.300+1.81%
Market Closed Jul 18 16:01 CST
484.52BMarket Cap65.35P/E (TTM)

About HENGRUI PHARMA Company

The company was founded in 1970 and listed on the Shanghai Stock Exchange in 2000. It is an innovative international pharmaceutical enterprise focusing on R&D, production and promotion of high-quality drugs. It focuses on research and development of new drugs in the fields of oncology, metabolic and cardiovascular diseases, immune and respiratory diseases, and neuroscience. It is one of the leading pharmaceutical companies with the most innovative capabilities in China. The company's main business involves R&D, production and sales of pharmaceuticals. Main products: pyrrolidinib maleate tablets, carrilizumab for injection, reverulamide tablets, hetrapopa ethanolamine tablets, iodophorol injections, butorphinol tartrate injections, etc. Corporate honors: “Environmental Exemplary Enterprise” and “Leading Green Development Enterprise” in Jiangsu Province, won the Lianyungang Economic and Technological Development Zone Enterprise “Environmental Protection Quality Award” in 2023, won the honorary title of “First Batch of Sterile Drug Quality Assurance Enterprises” issued by the China Pharmaceutical Quality Management Association, and the honorary title of “Jiangsu Pharmaceutical Industry Excellent Quality Management Enterprise” issued by the Jiangsu Pharmaceutical Quality Management Association; the company's “Young Eagle QC Group” and “Yuanzhi QC Group” were rated as Jiangsu Pharmaceutical Industry Quality Management (QC) Excellent Exchange Group and Jiangsu “Green Development Leader” Company” etc.

Company Profile

Symbol01276
Company NameHENGRUI PHARMA
ISINCNE100006XS6
Listing DateMay 23, 2025
Issue Price44.05
Shares Offered224.52M share(s)
FoundedApr 28, 1997
Registered AddressChina
Chairmanpiaoyang sun
Secretaryyingxianliuxiaohan liang
Audit InstitutionErnst & Young
Company CategoryMainland registration of Mainland Individuals control
Registered OfficeNo. 38 Huanghe Road, Lianyungang Economic and Technological Development Zone, Jiangsu
Head Office and Principal Place of BusinessRoom 1920, 19th floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong, China
Fiscal Year Ends12-31
Employees20325
MarketHong Kong motherboard
Phone021-61053323
Fax021-61063801
Emailir@hengrui.com
BusinessTablets (including antineoplastic agents), oral solutions, suspensions, sterile raw materials (antineoplastic agents), raw materials (including antineoplastic drugs), psychotropic drugs, softgels (including antineoplastic drugs), freeze-dried powder injections (including antineoplastic drugs, cephalosporins), inhaled powders, oral suspensions, oral emulsions, high-volume injections (containing multi-layer co-extruded infusion bags, containing anti-tumor drugs), small-volume injections (containing non-antitumor drugs) Sterilized), bioengineered products (polyethylene glycol recombinant human granulocyte stimulating factor injection), hard capsules (including antineoplastic agents), granules Manufacture of agents (antineoplastic drugs), powders, membranes, gels, and creams; pre-treatment and extraction of traditional Chinese medicines; R&D, manufacture and sale of medical devices; sales of general chemical products; self-employment and agency of import and export business of various commodities and technologies, with the exception of goods and technologies operated by companies restricted by the state or prohibited from being imported and exported.

Company Executives

  • Name
  • Position
  • Salary
  • piaoyang sun
  • Chairman, Executive Director, Chairman of the Strategy Committee, Nomination Committee Members
  • 1.65M
  • hongbin dai
  • Vice Chairman, Executive Director, Member of the Remuneration and Assessment Committee, Strategy Committee Members
  • 7.43M
  • ji feng
  • Executive Director, General Manager (President), Chief Operating Officer
  • --
  • lianshan zhang
  • Executive Vice President, Executive Director, Strategy Committee Members
  • 6.05M
  • ningjun jiang
  • Executive Vice President, Executive Director, Chief Strategy Officer, Strategy Committee Members, Authorized Representative
  • 6.78M
  • jieping sun
  • Executive Director, Senior Vice President
  • 3.82M
  • congzhao guo
  • Non-executive Directors, Strategy Committee Members
  • --
  • jiahong dong
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Strategy Committee Members, Audit Committee Members
  • --
  • qingsheng ceng
  • Independent Non-Executive Director, Chairman of the Audit Committee, Member of the Remuneration and Assessment Committee
  • --
  • jinyun sun
  • Independent Non-Executive Director, Chairman of the Remuneration and Assessment Committee, Nomination Committee Members, Audit Committee Members
  • --
  • jien zhou
  • Independent Non-Executive Director
  • --
  • kaihong yuan
  • Chairman of the Supervisory Board
  • 2.73M
  • guoqiang xiong
  • Auditors
  • 345.00K
  • yu xu
  • Employee Supervisors
  • 463.00K
  • jianjun liu
  • Chief Financial Officer
  • --
  • xiaohan liu
  • Joint Company Secretary, Board Secretary
  • --
  • yingxian liang
  • Joint Company Secretary, Authorized Representative
  • --

Market Insights

Robotics Investment Opportunities Robotics Investment Opportunities

Robotics includes companies involved in the design, creation, and manufacture of robots. These machines can perform tasks autonomously or semi-autonomously, often with the aim of improving efficiency, productivity, and safety across various industries. Robotics companies are rapidly innovating new technology with applications across many industries. They offer opportunities for growth and efficiency, align with long-term automation trends, and have the potential for disruption in emerging markets, making them appealing to investors. Robotics includes companies involved in the design, creation, and manufacture of robots. These machines can perform tasks autonomously or semi-autonomously, often with the aim of improving efficiency, productivity, and safety across various industries. Robotics companies are rapidly innovating new technology with applications across many industries. They offer opportunities for growth and efficiency, align with long-term automation trends, and have the potential for disruption in emerging markets, making them appealing to investors.

Unlock Now

Discussing

Focus on tariff dynamics! How to plan most securely in the near future?
Recently, Trump's tariffs have sparked controversy again. Trump stated that the United States would impose a 100% tariff on Russia, a 30% ta Show More

Positive signs keep on coming! China's assets explode across the board

Following the announcement of a series of previous stimulus policies, and DeepSeek's popularity with its low cost and high performance advantages, China Securities sounded the horn of counterattack this year.